Published in Transplantation on November 15, 2002
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Liver transplantation. Gut Liver (2009) 0.93
Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol (2004) 0.91
Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci (2010) 0.83
Biliary epithelial senescence and plasticity in acute cellular rejection. Am J Transplant (2013) 0.76
Histological and Clinicopathological Evaluation of Liver Allograft Biopsy: An Initial Experience of Fifty Six Biopsies. J Clin Diagn Res (2015) 0.75
Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation. Medicine (Baltimore) (2016) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Map-based cloning of a protein kinase gene conferring disease resistance in tomato. Science (1993) 9.00
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Kidney transplantation under FK 506. JAMA (1990) 7.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Apolipoproteins and ischaemic heart disease: implications for screening. Lancet (1994) 6.62
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Superconductivity at 43 K in SmFeAsO1-xFx. Nature (2008) 3.80
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45
Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39
A member of the tomato Pto gene family confers sensitivity to fenthion resulting in rapid cell death. Plant Cell (1994) 2.39
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem (1987) 2.30
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Brief report: treatment of a laboratory-acquired Sabiá virus infection. N Engl J Med (1995) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res (2001) 2.22
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem (1995) 2.20
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15